184 related articles for article (PubMed ID: 33650297)
21. The interaction between the internal clock and antidepressant efficacy.
Racagni G; Riva MA; Popoli M
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S9-S14. PubMed ID: 17917564
[TBL] [Abstract][Full Text] [Related]
22. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT
Duroux R; Rami M; Landagaray E; Ettaoussi M; Caignard DH; Delagrange P; Melnyk P; Yous S
Eur J Med Chem; 2017 Dec; 141():552-566. PubMed ID: 29102176
[TBL] [Abstract][Full Text] [Related]
24. Agomelatine: innovative pharmacological approach in depression.
Popoli M
CNS Drugs; 2009; 23 Suppl 2():27-34. PubMed ID: 19708723
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological evaluation of magnolol derivatives as melatonergic receptor agonists with potential use in depression.
Yang TH; Ma YB; Geng CA; Yan DX; Huang XY; Li TZ; Zhang XM; Chen JJ
Eur J Med Chem; 2018 Aug; 156():381-393. PubMed ID: 30015074
[TBL] [Abstract][Full Text] [Related]
26. Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.
Kamal M; Gbahou F; Guillaume JL; Daulat AM; Benleulmi-Chaachoua A; Luka M; Chen P; Kalbasi Anaraki D; Baroncini M; Mannoury la Cour C; Millan MJ; Prevot V; Delagrange P; Jockers R
J Biol Chem; 2015 May; 290(18):11537-46. PubMed ID: 25770211
[TBL] [Abstract][Full Text] [Related]
27. ACS chemical neuroscience molecule spotlight on Valdoxen.
Hopkins CR
ACS Chem Neurosci; 2010 Dec; 1(12):772-3. PubMed ID: 22778814
[TBL] [Abstract][Full Text] [Related]
28. [Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan)].
Tabeeva GR; Sergeev AV; Gromova SA
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9):32-6. PubMed ID: 22027667
[TBL] [Abstract][Full Text] [Related]
29. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
[TBL] [Abstract][Full Text] [Related]
30. Circadian rhythms, melatonin and depression.
Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
[TBL] [Abstract][Full Text] [Related]
31. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.
Bertaina-Anglade V; la Rochelle CD; Boyer PA; Mocaër E
Behav Pharmacol; 2006 Dec; 17(8):703-13. PubMed ID: 17110796
[TBL] [Abstract][Full Text] [Related]
32. Evidence of agomelatine's antidepressant efficacy: the key points.
Eser D; Baghai TC; Möller HJ
Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S15-9. PubMed ID: 17917562
[TBL] [Abstract][Full Text] [Related]
33. Acute toxicity and genotoxicity studies on new melatonergic antidepressant GW117.
Gao M; Ma H; Liu T; Cao C; Zheng Z; Tang L; Gu W; Zhang D; Sun H
Heliyon; 2023 Mar; 9(3):e14026. PubMed ID: 36915542
[TBL] [Abstract][Full Text] [Related]
34. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.
Bourin M; Mocaër E; Porsolt R
J Psychiatry Neurosci; 2004 Mar; 29(2):126-33. PubMed ID: 15069466
[TBL] [Abstract][Full Text] [Related]
35. Agomelatine, an innovative pharmacological response to unmet needs.
Le Strat Y; Gorwood P
J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
[TBL] [Abstract][Full Text] [Related]
36. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.
San L; Arranz B
Eur Psychiatry; 2008 Sep; 23(6):396-402. PubMed ID: 18583104
[TBL] [Abstract][Full Text] [Related]
37. Melatonin, selective and non-selective MT1/MT2 receptors agonists: differential effects on the 24-h vigilance states.
Ochoa-Sanchez R; Comai S; Spadoni G; Bedini A; Tarzia G; Gobbi G
Neurosci Lett; 2014 Feb; 561():156-61. PubMed ID: 24406151
[TBL] [Abstract][Full Text] [Related]
38. The Novel Pimavanserin Derivative ST-2300 with Histamine H
Venkatachalam K; Zhong S; Dubiel M; Satała G; Sadek B; Stark H
Biomolecules; 2022 May; 12(5):. PubMed ID: 35625611
[TBL] [Abstract][Full Text] [Related]
39. Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006.
Norman TR; Cranston I; Irons JA; Gabriel C; Dekeyne A; Millan MJ; Mocaër E
Eur J Pharmacol; 2012 Jan; 674(1):27-32. PubMed ID: 22040921
[TBL] [Abstract][Full Text] [Related]
40. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
